Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.2    
    

 
 

Momenta Pharmaceuticals, Inc.
  
    Nonstatutory Stock Option Agreement
  Granted Under 2004 Stock Incentive Plan    
    

1.     Grant of Option. 

        This
agreement evidences the grant by Momenta Pharmaceuticals, Inc., a Delaware corporation (the "Company"), on
[                        ],
200[    ] (the "Grant Date") to [                        ], an  [employee]/[consultant]
/[director] of the Company (the "Participant"), of an
option to purchase, in whole or in part, on the terms provided herein and in the Company's 2004 Stock Incentive Plan (the "Plan"), a total of
[                        ] shares (the
"Shares") of common stock, $0.0001 par value per share, of the Company ("Common Stock") at $[            ] per Share. Unless earlier terminated, this option shall expire at
5:00 p.m., Eastern time, on [                        ] (the "Final Exercise Date"). 

        It
is intended that the option evidenced by this agreement shall not be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and
any regulations promulgated thereunder (the "Code"). Except as otherwise indicated by the context, the term "Participant", as used in this option, shall be deemed to include any person who acquires
the right to exercise this option validly under its terms. 

2.     Vesting Schedule. 

        This
option will become exercisable ("vest") as to [    ]% of the original number of Shares on the  
[            ] anniversary of the Grant Date and as to an additional  [      ]% of the
original number of Shares at the end of each successive  [            ] period following the first anniversary of the Grant Date until the
 [            ] anniversary of the Grant Date.
 

        The
right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole
or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan. 

3.     Exercise of Option. 

        (a)    Form of Exercise.    Each election to exercise this option shall be by written
notice in the form attached hereto as Exhibit A, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, and
payment in full in the manner provided in the Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any
fractional share. 

        (b)    Continuous Relationship with the Company Required.    Except as otherwise provided
in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, officer
or director of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan
(an "Eligible Participant"). 

        (c)    Termination of Relationship with the Company.    If the Participant ceases to be
an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but
in no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent that the Participant was entitled to
exercise this option on the date of such cessation. Notwithstanding the foregoing, if the 

Participant,
prior to the Final Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other
agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon written notice to the Participant from the Company describing such violation. 

        (d)    Exercise Period Upon Death or Disability.    If the Participant dies or becomes
disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship
for "cause" as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant
(or in the case of death by an authorized transferee), provided that this option shall be exercisable only to the extent that this option was
exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date. 

        (e)    Discharge for Cause.    If the Participant, prior to the Final Exercise Date, is
discharged by the Company for "cause" (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such discharge. "Cause" shall mean willful misconduct
by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any
employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination
shall be conclusive. The Participant shall be considered to have been discharged for "Cause" if the Company determines, within 30 days after the Participant's resignation, that discharge for
cause was warranted. 

4.     Withholding. 

        No
Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any
federal, state or local withholding taxes required by law to be withheld in respect of this option. 

5.     Nontransferability of Option. 

        This
option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent
and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 

6.     Provisions of the Plan. 

        This
option is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this option. 

        IN
WITNESS WHEREOF, the Company has caused this option to be executed under its corporate seal by its duly authorized officer. This option shall take effect as a sealed instrument. 

	 	 	MOMENTA PHARMACEUTICALS, INC.
	

Dated:	
 	

By:	

 
	 	 	 	

	

 	
 	

Name:	

 
	 	 	 	

	 	 	Title:	 
	 	 	 	

PARTICIPANT'S ACCEPTANCE 

        The
undersigned hereby accepts the foregoing option and agrees to the terms and conditions thereof. The undersigned hereby acknowledges receipt of a copy of the Company's 2004 Stock
Incentive Plan. 

	 	 	PARTICIPANT:
	

 	
 	

	

 	
 	

Address:	

 
	 	 	 	

	

 	
 	

 	

EXHIBIT A

NOTICE OF STOCK OPTION EXERCISE 

Date:  

Participant
name and address: 

Attention:
Treasurer 

Dear
Sir or Madam: 

        I
am the holder of an Nonstatutory Stock Option granted to me under the Momenta Pharmaceuticals, Inc. (the "Company") 2004 Stock Incentive Plan on
                 for the purchase of                  shares of Common Stock
of the Company at a purchase price of
$                 per share. 

        I
hereby exercise my option to purchase                  shares of Common Stock (the "Shares"), for which I have enclosed
                 in the amount of $                . Please register my
stock certificate as follows: 

	 	 	 	 	(check applicable box)
	

Name(s):	
 	

	
 	

o	
 	

TEN COM
	

 	
 	

	
 	

o	
 	

TEN ENT
	

Address:	
 	

	
 	

o	
 	

JT TEN
	

Tax I.D. #:	
 	

	
 	

o	
 	

UNIF GIFT MIN ACT

        I
represent, warrant and covenant as follows: 

        1.     I
am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of
the Securities Act of 1933 (the "Securities Act"), or any rule or regulation under the Securities Act. 

        2.     I
have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits
and risks of my investment in the Company. 

        3.     I
have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed
investment decision with respect to such purchase. 

        4.     I
can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period. 

        5.     I
understand that (i) the Shares have not been registered under the Securities Act and are "restricted securities" within the meaning of Rule 144 under the
Securities Act, (ii) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then
available; (iii) in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then
exists for the Common Stock, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is
now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares
under the Securities Act. 

Very
truly yours, 

(Signature) 

QuickLinks

Exhibit 10.2

Momenta Pharmaceuticals, Inc. Nonstatutory Stock Option Agreement Granted Under 2004 Stock Incentive PlanQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.3    
    

Confidential
Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions. 

 
 

FOURTH AMENDMENT TO THE NOVEMBER 1, 2002 LICENSE

        This
Fourth Amendment, effective as of the date set forth above the signatures of the parties below, pertains to the Amended and Restated Exclusive Patent License Agreement, effective on
November 1, 2002, as subsequently amended by a First Amendment on November 15, 2002, a Letter Agreement on September 12, 2003, a Letter Agreement on October 22, 2003, a
Second Amendment on November 19, 2003 and a Third Amendment on April 2,2004, by and between the Massachusetts Institute of Technology
("M.I.T.") and Momenta Pharmaceuticals, Inc. ("COMPANY"). 

        WHEREAS,
M.I.T. is the owner of certain new intellectual property closely related to the PATENT RIGHTS of the Amended and Restated Exclusive Patent License Agreement and desires to have
this technology developed and commercialized to benefit the public; and 

        WHEREAS,
COMPANY desires to add this new technology to the PATENT RIGHTS and M.I.T. is willing to grant a license thereunder. 

        NOW,
THEREFORE, M.I.T. and COMPANY hereby agree to modify the Amended and Restated Exclusive Patent License Agreement as follows: 

	1.
	The
patent rights of the following M.I.T. Case Nos. shall be added to the PATENT RIGHTS ENZYMES and the PATENT RIGHTS, as defined by their inclusion in the attached APPENDIX H: 

M.I.T. Case No. [**]

Entitled: [**]

By [**]

M.I.T. Case No. [**]

Entitled: [**]

By [**]

M.I.T. Case No. [**]

Entitled: [**]

By [**]

	2.
	In
consideration of the addition of the patent rights of M.I.T. Case Nos. [**], and [**] to the PATENT RIGHTS ENZYMES and the license
granted in the FIELD ENZYMES hereunder:

	a.
	COMPANY
shall pay M.I.T. a Patent Addition Fee of [**] dollars ($[**]) for each M.I.T. Case added for a total of
[**] dollars ($[**]), which shall be due within thirty (30) days of the Effective Date of this Fourth Amendment; and

	b.
	COMPANY
shall be responsible for payment of all fees and costs relating to the filing, prosecution and maintenance of the patent rights of M.I.T. Case Nos. [**]
and [**], whether such fees and costs were incurred [**] the Effective Date of this Fourth Amendment; provided, however, that should M.I.T. license the
PATENT RIGHTS ENZYMES to one or more third parties, M.I.T. shall promptly notify COMPANY in writing and any fees and costs associated with PATENT RIGHTS ENZYMES shall be allocated in a fair and
equitable manner between COMPANY and any subsequent licensees of the PATENT RIGHTS ENZYMES on a go-forward basis. 

All
other terms and conditions of the License Agreement shall remain unchanged. 

The EFFECTIVE DATE of this Amendment is July 17, 2004.

Agreed
to for: 

	MASSACHUSETTS INSTITUTE OF

TECHNOLOGY	MOMENTA PHARMACEUTICALS, INC.
	By	/s/ Lita L. Nelsen	By	/s/ Susan K. Whoriskey
	Name	Lita L. Nelsen	Name	Susan K. Whoriskey
	Title	Technology Licensing Officer	Title	Vice President, Licensing & Business Development
	Date	July 26, 04	Date	July 28, 2004

 
 

APPENDIX H
  PATENT RIGHTS ENZYMES

M.I.T. Case No. [**]

Entitled: [**]

By [**]

Patent
Convention Treaty Serial No. [**]

United States of America Serial No. [**]

Entitled: [**]

M.I.T. Case No. [**]

Entitled: [**]

By [**]

Patent
Convention Treaty Serial No. [**]

United States of America Serial No. [**]

Entitled: [**]

M.I.T. Case No. [**]

Entitled: [**] 

By [**]

Japan
Serial No. [**] 

Patent Convention Treaty Serial No. [**]

United States of America Serial No. [**]

Entitled: [**]

M.I.T. Case No. [**]

Entitled: [**]

By [**]

[**]

M.I.T. Case No. [**]

Entitled: [**]

By [**]

United
States of America Serial No. [**]

United States of America Serial No. [**]

Entitled: [**]

M.I.T. Case No. [**]

Entitled: [**]

By [**]

[**]  

QuickLinks

Exhibit 10.3

FOURTH AMENDMENT TO THE NOVEMBER 1, 2002 LICENSE

APPENDIX H PATENT RIGHTS ENZYMES

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00070-of-00352.parquet"}]]